William Makis et al., 2025-05-26: The underlying publication behind the August 2025 'breakthrough' coverage: a case series of three patients who self-administered fenbendazole alongside other non-chemotherapy treatments, two of whom reportedly reached complete remission. The article is a case series, not a trial, and now carries a retraction notice.
Retracted Paper – Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients
Article title, unpaginated
William Makis et al., 2025-05-26: The underlying publication behind the August 2025 'breakthrough' coverage: a case series of three patients who self-administered fenbendazole alongside other non-chemotherapy treatments, two of whom reportedly reached complete remission. The article is a case series, not a trial, and now carries a retraction notice. Study type: case series, n=3 (breast, prostate, melanoma), self-administered veterinary antiparasitic, no control group, no randomisation, retrospective follow-up of 11 months to nearly 3 years. Funder/conflicts: the retraction (CHF-35) records an undeclared conflict – the first author offered services related to the subject of the study. Maker: generic fenbendazole, patent expired early 1990s (Hoechst/Sanofi origin). Note the patients' remissions are attributed by the authors to a combination of therapies excluding chemotherapy, so the series cannot isolate fenbendazole. PubMed 40605964; PMC12215191. Study type: case report.
